Earlier this year, researchers at CHOP and Penn created a first-of-its-kind drug customized to a unique genetic mutation to save an infant named Baby KJ from dying of a rare liver disorder. KJ Muldoon ...
Ecuadorian scientists have, for the first time, edited the gene of a fungus that destroys banana plantations. Using an ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
Part 4 of the TED Radio Hour episode Augmenting Humans. Jennifer Doudna's gene-editing technology CRISPR can now manipulate populations of microbes. This new field, called precision microbiome editing ...
The baby's disease prevented the liver from removing ammonia Half of babies with the disease die in their first week of life The baby has already shown signs of improvement The baby's disease ...
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as the company investigates and works with regulators on its CRISPR-based ...
Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...
17d
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback